Condition: Heart Failure With Preserved Ejection Fraction · Heart Failure With Mildly Reduced Ejection Fraction · Obesity · Sponsor: Amgen
This trial will examine if maridebart cafraglutide as an adjunct to standard of care will lead to a reduction in heart failure (HF) events such as HF hospitalizations and urgent HF visits, cardiovascular (CV) deaths and improvement in HF symptoms in participants with HF with preserved ejection fraction (HFpEF) and HF with mildly reduced ejection fraction (HFmrEF) who are obese. This is a phase 3, global, multicenter, 2-part trial with a double-blind period and an open-label extension (OLE). The trial is event-driven, and Part 1 will conclude when approximately 850 primary endpoint events have occurred.
This description comes directly from the study's public registry record.
Amgen Call Center · 866-572-6436 · medinfo@amgen.com
Always discuss trial participation with your own doctor first.
| University of Alabama Saint Vincent's Birmingham | Birmingham, Alabama, United States | Recruiting |
| SEC Clinical Research | Dothan, Alabama, United States | Recruiting |
| Eastern Shore Research Institute | Fairhope, Alabama, United States | Recruiting |
| Heart Center Research LLC | Huntsville, Alabama, United States | Recruiting |
| HonorHealth | Phoenix, Arizona, United States | Recruiting |
| Medical Advancement Centers of Arizona | Phoenix, Arizona, United States | Recruiting |
| Pima Heart and Vascular Clinical Research | Tucson, Arizona, United States | Recruiting |
| Yuma Clinical Trials | Yuma, Arizona, United States | Recruiting |
| Arkansas Cardiology | Little Rock, Arkansas, United States | Recruiting |
| National Heart Institute | Beverly Hills, California, United States | Recruiting |
| Valley Clinical Trials, LLC dba Flourish Research | Covina, California, United States | Recruiting |
| National Institute of Clinical Research | Huntington Beach, California, United States | Recruiting |
+ 616 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07037459